Section Arrow
AKTS.NASDAQ
- Aktis Oncology Inc
Quotes are at least 15-min delayed:2026/11/04 13:18 EST
Regular Hours
Last
 15.09
+0.15 (+1.00%)
Day High 
16.11 
Prev. Close
14.94 
1-M High
18.75 
Volume 
98.42K 
Bid
15.04
Ask
15.12
Day Low
14.695 
Open
15.29 
1-M Low
13.96 
Market Cap 
830.96M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 16.02 
20-SMA 16.34 
50-SMA 20.16 
52-W High 34.1899 
52-W Low 13.96 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.32/-2.65
Enterprise Value
841.19M
Balance Sheet
Book Value Per Share
8.72
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CRISCuris Inc.1.2499+0.536+75.08%0.2PE
KPTIKaryopharm Therapeutics Inc.0.09+0.0017+1.93%-- 
GERNGeron Corp1.035+0.105+11.29%-- 
INOInovio Pharmaceuticals1.73+0.07+4.22%-- 
RXRXRecursion Pharmaceuticals3.89+0.21+5.71%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company hasone operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.